Carteolol ophthalmic Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Dec 5, 2022.
Carteolol ophthalmic is also known as: Ocupress
Carteolol ophthalmic Pregnancy Warnings
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: C
Comments:
-A risk for intra uterine growth retardation has been shown when beta-blockers are administered orally.
-Signs and symptoms of beta blockade (e.g., bradycardia, hypotension, respiratory distress and hypoglycemia) have been reported in neonates when beta-blockers have been administered until delivery.
-Neonates should be monitored during the first days of life.
Animal studies have revealed increased resorptions and decreased fetal weights. There are no adequate and well-controlled studies in pregnant women.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Carteolol ophthalmic Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Yes
Comments: The effects in the nursing infant are unknown.
See also
References for pregnancy information
- "Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
References for breastfeeding information
- "Product Information. Ocupress (carteolol ophthalmic)." Ciba Vision Ophthalmics (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
